Of 1038 treated patients in the phase III trial , 38 % had mild renal impairment ( creatinine clearance > 50 to 80 mL/min ; n = 198 for nab-P/C and n = 206 for sb-P/C ) and 5 % had moderate renal impairment ( creatinine clearance 50 mL/min : n = 26 for nab-P/C and n = 27 for sb-P/C ) .